Cosentyx is a biologic medication used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the drug's patent information [1], it works by blocking the activity of a protein called interleukin-17A, which is involved in the inflammatory response that causes symptoms in these conditions.

In the case of non-radiographic axial spondyloarthritis (nr-axSpA), a type of inflammatory arthritis that affects the spine, Cosentyx has been shown to improve symptoms in clinical trials [2]. One study published in the Annals of Rheumatic Diseases [3] found that patients with nr-axSpA who received Cosentyx had significant improvements in their spinal inflammation and overall disease activity compared to those who received a placebo.

Patients with psoriasis and psoriatic arthritis have also reported improvements in their symptoms with Cosentyx treatment, including reduced joint pain and skin lesions [1]. However, it is important to note that individual responses to the medication may vary, and some patients may not experience significant improvements or may experience side effects.

Overall, Cosentyx has been shown to be an effective treatment option for various autoimmune conditions, including nr-axSpA, by targeting the underlying inflammation that causes symptoms. However, as with any medication, it is important to discuss the potential benefits and risks with a healthcare provider to determine if it is the right treatment option for an individual patient.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/non-radiographic-axial-spondyloarthritis/treatment-facts
[3] https://ard.bmj.com/content/77/6/890